Alterity Therapeutics
ATHE
9 hedge funds and large institutions have $295K invested in Alterity Therapeutics in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
10% less funds holding
Funds holding: 10 → 9 (-1)
18% less capital invested
Capital invested by funds: $361K → $295K (-$66K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.9K |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
+$67 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$17K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.43K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$466 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $273K | +$12.9K | +1,162 | +5% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $14K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $3K | -$4.43K | -399 | -63% |
|
|
AG
4
Advisor Group
Phoenix,
Arizona
| $3K | – | – | – |
|
|
AIM
5
Advantage Investment Management
Cedar Rapids,
Iowa
| $1K | – | – | – |
|
|
NFG
6
Next Financial Group
Houston,
Texas
| $1K | – | – | – |
|
|
APA
7
American Portfolios Advisors
Holbrook,
New York
| $95 | – | – | – |
|
|
OMC
8
Old Mission Capital
Chicago,
Illinois
| – | -$17K | -1,271 | Closed |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$15K | -1,145 | Closed |
|
|
10
Wells Fargo
San Francisco,
California
| – | -$466 | -42 | -84% |
|
|
SPIA
11
Steward Partners Investment Advisory
New York
| – | +$67 | +6 | New |
|
ATHE Hedge Fund Activity: Q3 2019 in Review
9 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q3 2019, worth a combined $295K — down 18% from $361K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ATHE and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $12.9K. The largest seller was Old Mission Capital, exiting entirely with an estimated $17K sold.
- 9 institutional investors held Alterity Therapeutics (ATHE) as of Q3 2019, down from 10 in Q2 2019.
- Funds reported $295K of Alterity Therapeutics stock for Q3 2019, down 18% quarter-over-quarter.
- 1 fund opened new Alterity Therapeutics positions in Q3 2019 and 2 closed out, a net change of -1 holder.
- The largest Alterity Therapeutics buyer in Q3 2019 was Morgan Stanley, an estimated $12.9K added.
- The largest Alterity Therapeutics seller in Q3 2019 was Old Mission Capital, an estimated $17K sold.
Based on aggregated 13F filings for Q3 2019.